{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:23Z","timestamp":1791908183343,"version":"4.3.4"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>First-generation somatostatin receptor ligands (fg-SRLs) represent the first-line medical treatment for acromegaly, recommended in patients with persistent disease after neurosurgery, or when surgical approach is not feasible. Despite the lack of\u00a0strong recommendations from guidelines and consensus statements, data from national Registries report an increasing use of medical therapy as first-line treatment in\u00a0acromegaly.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We retrospectively evaluated the potential role of a large number of clinical and radiological parameters in predicting the biochemical response to 6-month treatment with fg-SRLs, in a cohort of na\u00efve acromegaly patients referred to a single tertiary center for pituitary diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Univariable and multivariable logistic regression and linear regression analyses were performed. Biochemical response was defined based on IGF-1 levels, represented as both categorical (tight control, control, &amp;gt;50% reduction) and continuous (linear % reduction) variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty-one patients (33 females, median age 57 years) were included in the study. At univariable logistic regression analysis, we found that younger age (\u2264 40 years; OR 0.04, p=0.045) and higher BMI (OR 0.866, p=0.034) were associated with a lower chance of achieving &amp;gt;50% IGF-1 reduction. On the contrary, higher IGF-1 xULN values at diagnosis (OR 2.304, p=0.007) and a T2-hypointense tumor (OR 18, p=0.017) were associated with a significantly higher likelihood of achieving &amp;gt;50% IGF-1 reduction after SRL therapy. Of note, dichotomized age, IGF1 xULN at diagnosis, and T2-hypointense signal of the tumor were retained as significant predictors by our multivariable logistic regression model. Furthermore, investigating the presence of predictors to the linear % IGF-1 reduction, we found a negative association with younger age (\u2264 40 years; \u03b2 -0.533, p&amp;lt;0.0001), while a positive association was observed with both IGF-1 xULN levels at\u00a0diagnosis (\u03b2 0.330, p=0.018) and the presence of a T2-hypointense pituitary tumor\u00a0(\u03b2\u00a00.466, p=0.019). All these variables were still significant predictors at multivariable analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Dichotomized age, IGF-1 levels at diagnosis, and tumor T2-weighted signal are reliable predictors of both &amp;gt;50% IGF-1 reduction and linear % IGF-1 reduction after 6 month fg-SRL treatment in na\u00efve acromegaly patients. These parameters should be considered in the light of an individualized treatment for acromegaly patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.677919","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T15:47:55Z","timestamp":1620402475000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective"],"prefix":"10.3389","volume":"12","author":[{"given":"Federica","family":"Nista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Corica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Castelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Khorrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cocchiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Zoppoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Prior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Criminelli","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Zona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-Tumor Endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0701-2","article-title":"Incidence and Prevalence of Acromegaly in a Large US Health Plan Database","volume":"19","author":"Burton","year":"2016","journal-title":"Pituitary"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1630-4","article-title":"Epidemiology of Acromegaly in Italy: Analysis From a Large Longitudinal Primary Care Database","volume":"61","author":"Gatto","year":"2018","journal-title":"Endocrine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0022","article-title":"Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1764-4","article-title":"Signs and Symptoms of Acromegaly At Diagnosis: The Physician\u2019s and the Patient\u2019s Perspectives in the ACRO-POLIS Study","volume":"63","author":"Caron","year":"2019","journal-title":"Endocrine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s183360","article-title":"Octreotide-Resistant Acromegaly: Challenges and Solutions","volume":"16","author":"Corica","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"B8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: An Endocrine Society Clinical Practice Guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on Acromegaly Therapeutic Outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary Management of Acromegaly: A Consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/bf03345797","article-title":"Pre-Surgical Treatment With Somatostatin Analogues in Patients With Acromegaly: The Case for","volume":"35","author":"Ferone","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/bf03345798","article-title":"Pre-Surgical Treatment With Somatostatin Analogues in Patients With Acromegaly: The Case Against","volume":"35","author":"Losa","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0853-x","article-title":"Pros and Cons in Endocrine Practice: Pre-Surgical Treatment With Somatostatin Analogues in Acromegaly","volume":"52","author":"Losa","year":"2016","journal-title":"Endocrine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0619-5","article-title":"Impact of Pre-Treatment With Somatostatin Analogs on Surgical Management of Acromegalic Patients Referred to a Single Center","volume":"51","author":"Bacigaluppi","year":"2016","journal-title":"Endocrine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0384-x","article-title":"Changes in Acromegaly Treatment Over Four Decades in Spain: Analysis of the Spanish Acromegaly Registry (Rea)","volume":"16","author":"Sesmilo","year":"2013","journal-title":"Pituitary"},{"key":"B17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/EJE-07-0358","article-title":"Acrobel\u2013the Belgian Registry on Acromegaly: A Survey of the \u2018Real-Life\u2019 Outcome in 418 Acromegalic Subjects","volume":"157","author":"Bex","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the Management and Comorbidities of Acromegaly Over Three Decades: The French Acromegaly Registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0623","article-title":"Comorbidities, Treatment Patterns and Cost-of-Illness of Acromegaly in Sweden: A Register-Linkage Population-Based Study","volume":"176","author":"Lesen","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting Biochemical Control Response Rates With First-Generation Somatostatin Analogues in Acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"key":"B21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive Factors for Responses to Primary Medical Treatment With Lanreotide Autogel 120\u00a0mg in Acromegaly: Post Hoc Analyses From the PRIMARYS Study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/er.2010-0002","article-title":"Resistance to Somatostatin Analogs in Acromegaly","volume":"32","author":"Colao","year":"2011","journal-title":"Endocr Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/JME-14-0011","article-title":"Somatostatin Receptor Ligands and Resistance to Treatment in Pituitary Adenomas","volume":"52","author":"Cuevas-Ramos","year":"2014","journal-title":"J Mol Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of Pituitary Adenoma on T2-weighted Magnetic Resonance Imaging Predicts the Response to Octreotide Treatment in Newly Diagnosed Acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic Resonance Imaging as a Predictor of Response to Somatostatin Analogs in Acromegaly After Surgical Failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-017-0788-8","article-title":"T2-Weighted MRI Signal Intensity as a Predictor of Hormonal and Tumoral Responses to Somatostatin Receptor Ligands in Acromegaly: A Perspective","volume":"20","author":"Potorac","year":"2017","journal-title":"Pituitary"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0356","article-title":"T2-Weighted MRI Signal Predicts Hormone and Tumor Responses to Somatostatin Analogs in Acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2019.06.04","article-title":"Pituitary Magnetic Resonance Imaging Predictive Role in the Therapeutic Response of Growth Hormone-Secreting Pituitary Adenomas","volume":"8","author":"Tortora","year":"2019","journal-title":"Gland Surg"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity Score Using an anti-SST2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment With Somatostatin Analogs in Acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, But Not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide","volume":"98","author":"Casar-Borota","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13851","article-title":"E-Cadherin Expression is Associated With Somatostatin Analogue Response in Acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular Profiling for Acromegaly Treatment: A Validation Study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0349","article-title":"KI-67 is a Predictor of Acromegaly Control With Octreotide LAR Independent of SSTR2 Status and Relates to Cytokeratin Pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.11.6112","article-title":"Impaired Cardiac Performance in Elderly Patients With Growth Hormone Deficiency","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-015-2699-7","article-title":"Assessing Size of Pituitary Adenomas: A Comparison of Qualitative and Quantitative Methods on MR","volume":"158","author":"Davies","year":"2016","journal-title":"Acta neurochirurgica"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0305","article-title":"Pituitary MRI Characteristics in 297 Acromegaly Patients Based on T2-weighted Sequences","volume":"22","author":"Potorac","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04200.x","article-title":"Balance Between Somatostatin and D2 Receptor Expression Drives TSH-secreting Adenoma Response to Somatostatin Analogues and Dopastatins","volume":"76","author":"Gatto","year":"2012","journal-title":"Clin Endocrinol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02073","article-title":"The Octreotide Test Dose is Not a Reliable Predictor of the Subsequent Response to Somatostatin Analogue Therapy in Patients With Acromegaly","volume":"154","author":"Pokrajac","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02191.x","article-title":"The Value of an Acute Octreotide Suppression Test in Predicting Long-Term Responses to Depot Somatostatin Analogues in Patients With Active Acromegaly","volume":"62","author":"Karavitaki","year":"2005","journal-title":"Clin Endocrinol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2005.02.007","article-title":"Intravenous Octreotide Test Predicts the Long Term Outcome of Treatment With Octreotide-Long-Acting Repeatable in Active Acromegaly","volume":"15","author":"Biermasz","year":"2005","journal-title":"Growth hormone IGF Res Off J Growth Hormone Res Soc Int IGF Res Soc"},{"key":"B42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/eje.1.01935","article-title":"Limited Predictive Value of an Acute Test With Subcutaneous Octreotide for Long-Term IGF-I Normalization With Sandostatin LAR in Acromegaly","volume":"153","author":"de Herder","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0884-4","article-title":"How are Growth Hormone and Insulin-Like Growth Factor-1 Reported as Markers for Drug Effectiveness in Clinical Acromegaly Research? A Comprehensive Methodologic Review","volume":"21","author":"van Esdonk","year":"2018","journal-title":"Pituitary"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel Pathway for Somatostatin Analogs in Patients With Acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab: TEM"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01360","article-title":"Paradoxical GH Increase During Ogtt Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly","volume":"104","author":"Scaroni","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000192","article-title":"Laboratory Investigations in the Diagnosis and Follow-Up of GH-related Disorders","volume":"63","author":"Schilbach","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03556.x","article-title":"Monitoring of Acromegaly: What Should be Performed When GH and IGF-1 Levels are Discrepant","volume":"71","author":"Freda","year":"2009","journal-title":"Clin Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/clinem\/dgaa859","article-title":"Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cut-Offs and Mean Values Assessment","volume":"106","author":"Campana","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative Analyses of T2-weighted MRI as a Potential Marker for Response to Somatostatin Analogs in Newly Diagnosed Acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial","volume":"99","author":"Caron","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0816-2","article-title":"MRI T2 Characteristics in Somatotroph Adenomas Following Somatostatin Analog Treatment in Acromegaly","volume":"53","author":"Heck","year":"2016","journal-title":"Endocrine"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-018-0877-3","article-title":"Clinicopathological Significance of Baseline T2-weighted Signal Intensity in Functional Pituitary Adenomas","volume":"21","author":"Dogansen","year":"2018","journal-title":"Pituitary"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2282020695","article-title":"Comparison of Growth Hormone-Producing and non-Growth Hormone-Producing Pituitary Adenomas: Imaging Characteristics and Pathologic Correlation","volume":"228","author":"Hagiwara","year":"2003","journal-title":"Radiology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth Hormone Granulation Pattern and Somatostatin Receptor Subtype 2A Correlate With Postoperative Somatostatin Receptor Ligand Response in Acromegaly: A Large Single Center Experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2197","article-title":"The Expression of E-cadherin in Somatotroph Pituitary Adenomas is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.677919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T15:47:59Z","timestamp":1620402479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.677919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":55,"alternative-id":["10.3389\/fendo.2021.677919"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.677919","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"article-number":"677919"}}